Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Updated guidance is based on findings from the REPRIEVE trial, which showed pitavastatin reduced the risk of cardiovascular events by 35%.
In limited studies to date, semaglutide and other weight-loss drugs appear to be safe and effective for people living with HIV.
When given a choice, most women chose injectable cabotegravir over daily prevention pills.
We take a deep dive into the breaking science being released at IAS 2023 and explain why these breakthroughs are so important.
This year’s International AIDS Society (IAS) Conference on HIV Science was held over four days in Brisbane, Australia.
Certain drugs in this class may increase the likelihood of diabetes and hypertension, but cardiovascular risk factors can be managed.
Drug levels remained adequate throughout pregnancy, so no dose adjustment was needed.
COVID mortality declined overall during the omicron wave but less so for people with HIV.
Using two instead of three or four drugs could potentially lead to cost savings in the billions.
At three years, median height and bone mineral density were similar for children with and without tenofovir exposure in the womb.
Ruxolitinib might have contributed to a functional cure after a stem cell transplant without a rare mutation.
Global study highlights the importance of prompt HIV treatment and viral suppression to prevent severe monkeypox.
People who used once-weekly oral lenacapavir maintained viral suppression when injections were interrupted.
Person-centered care models that serve people living with HIV and key populations remain scarce and haphazardly implemented globally.
HIV.gov conversations about doxyPEP, HIV PrEP and the effectiveness of U=U.
NIH’s Carl Dieffenbach and Bill Kapogiannis interview experts about research presented at IAS 2023.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.